An aphorism of which we are by now all acutely aware: when you can’t breathe, nothing else matters.
Montreal-based Elixxer Ltd. (TSX-Venture: ELXR) announced Wednesday that its pharmaceutical partner, Freia launched production of ImmunoV Forte, to improve and protect respiratory function in the human body against airborne infections.
Freia is initiating clinical trials on the active ingredients in ImmunoV Forte that aid and protect the human respiratory tract from external environmental attacks such as respiratory viruses, bacteria, smoke and pollution.
In being compliant with Canadian Exchange regualators, both Elixxer and Freia are not making any expressed or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 at this time. Post trials, the company will update the market as to these results.
The product will be available for sale in Europe by mid-April.
ELXR shares garnered half a cent, or 16.7%, to 3.5 cents, on 8.5 million shares.
